ImmuPharma PLC (LSE:IMM) — Market Cap & Net Worth
Market Cap & Net Worth: ImmuPharma PLC (IMM)
ImmuPharma PLC (LSE:IMM) has a market capitalization of $269.44K (GBX2.21 Billion) as of June 21, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31037 globally and #989 in its home market, demonstrating a -3.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImmuPharma PLC's stock price GBX4.41 by its total outstanding shares 502723932 (502.72 Million). Review IMM total debt and obligations to assess the company's total debt and financial obligations.
ImmuPharma PLC Market Cap History: 2015 to 2026
ImmuPharma PLC's market capitalization history from 2015 to 2026. Data shows change from $1.84 Million to $269.44K (-16.58% CAGR).
Index Memberships
ImmuPharma PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.03% | #270 of 722 |
Weight: ImmuPharma PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ImmuPharma PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImmuPharma PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.44x
ImmuPharma PLC's market cap is 3.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.84 Million | $76.41K | -$3.90 Million | 24.02x | N/A |
| 2016 | $3.18 Million | $164.78K | -$5.32 Million | 19.30x | N/A |
| 2017 | $10.40 Million | $150.46K | -$6.22 Million | 69.11x | N/A |
| 2018 | $718.71K | $81.28K | -$7.21 Million | 8.84x | N/A |
| 2019 | $978.67K | $77.92K | -$6.12 Million | 12.56x | N/A |
| 2020 | $816.58K | $126.67K | -$6.86 Million | 6.45x | N/A |
| 2021 | $406.76K | $118.35K | -$8.17 Million | 3.44x | N/A |
Competitor Companies of IMM by Market Capitalization
Companies near ImmuPharma PLC in the global market cap rankings as of June 21, 2026.
Key companies related to ImmuPharma PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
ImmuPharma PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, ImmuPharma PLC's market cap moved from $1.84 Million to $ 269.44K, with a yearly change of -16.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX269.44K | -28.95% |
| 2025 | GBX379.24K | +414.52% |
| 2024 | GBX73.71K | -27.74% |
| 2023 | GBX102.00K | -9.38% |
| 2022 | GBX112.55K | -72.33% |
| 2021 | GBX406.76K | -50.19% |
| 2020 | GBX816.58K | -16.56% |
| 2019 | GBX978.67K | +36.17% |
| 2018 | GBX718.71K | -93.09% |
| 2017 | GBX10.40 Million | +226.92% |
| 2016 | GBX3.18 Million | +73.33% |
| 2015 | GBX1.84 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of ImmuPharma PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $269.44K USD |
| MoneyControl | $269.44K USD |
| MarketWatch | $269.44K USD |
| marketcap.company | $269.44K USD |
| Reuters | $269.44K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more